The therapeutic potential of Ma'aljobon, a whey product, in primary hypertension: A double-blind randomized controlled trial

Objective: Ma’aljobon is used in Persian medicine (PM) as a natural antihypertensive product. This study aimed to evaluate the hypotensive effect of Ma’aljobon in patients with uncontrolled grade ۱ primary hypertension (HTN).Materials and Methods: This double-blind, placebo-controlled clinical trial included ۱۱۴ patients (۲۰-۸۰ years) with uncontrolled grade ۱ primary HTN. After obtaining informed consent, the participants were randomly divided into two groups and administered with ۲۵g of Ma’aljobon or maltodextrin twice daily for six weeks. Systolic and diastolic blood pressures (SBP and DBP, respectively) were analyzed.Results: A total of ۹۷ patients (۵۲.۳±۱۰.۷ years, %۵۳.۶ female) completed the study. In the Ma’aljobon group, SBP decreased from ۱۵۰.۳±۱۲.۳ to ۱۳۰.۶±۱۲.۱ mm Hg, and DBP decreased from ۹۳.۳±۸.۲ to ۸۰.۱±۶.۶ mm Hg (p<۰.۰۰۱). In the control group, SBP decreased from ۱۴۷.۶±۱۱.۲ to ۱۳۸.۷±۱۴.۴ mm Hg, and DBP decreased from ۸۶.۶±۷.۷ to ۸۲.۲±۸.۲ mm Hg (p<۰.۰۰۱). There was a significant difference in the changes of SBP and DBP between the two groups over time (p<۰.۰۰۱). No adverse events were observed.Conclusion: Ma’aljobon has a stronger hypotensive effect than placebo in patients with HTN and can be recommended as an add-on therapy for uncontrolled HTN.

کلیدواژه ها:

Hypertension ، Persian Medicine ، Whey Proteins ، Traditional Medicine